CAPRICOR THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

30 Jul 2026 10:16:38 بحسب NetDania Notify

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

16 Dec 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

05 Dec 2025 06:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

04 Dec 2025 16:01:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

03 Dec 2025 09:45:22 بحسب NetDania Notify

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

03 Dec 2025 07:20:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

25 Nov 2025 11:20:23 بحسب NetDania Notify

NetDania - New 12 months Low: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

24 Nov 2025 09:49:02 بحسب NetDania Notify

Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025

24 Nov 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

10 Nov 2025 16:01:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

10 Nov 2025 13:50:11 بحسب NetDania Notify

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

03 Nov 2025 09:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

31 Oct 2025 09:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

25 Sep 2025 07:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

09 Sep 2025 09:20:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

18 Aug 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

11 Aug 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

08 Aug 2025 08:30:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

06 Aug 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy

28 Jul 2025 09:00:00 بحسب Nasdaq GlobeNewswire